secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001628280-23-015693
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q1 2023: Cash $97M, first patient dosed in ONSEMBLE trial
--------------------------------------------------------------------------

- Cash, cash equivalents & short-term investments of $97M as of March 31, 2023; projected runway into 2025.
- First patient dosed in Phase 2 ONSEMBLE trial of onvansertib for KRAS/NRAS-mutated metastatic CRC.
- Appointed Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer.
- Operating expenses $12.1M in Q1 2023, up from $11.1M in Q1 2022.
- Net cash used in operations $8.7M in Q1 2023, compared to $10.2M in Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/0001628280-23-015693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828023015693/crdf-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer